Serveur d'exploration Tocilizumab - Checkpoint (Ncbi)

Index « Auteurs » - entrée « Yoshiya Tanaka »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Yoshitsugu Miyazaki < Yoshiya Tanaka < Yoshiyuki Arinuma  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 40.
[0-20] [0 - 20][0 - 40][20-40]
Ident.Authors (with country if any)Title
000061 (2007) Yosuke Okada ; Masao Nawata ; Yoshiya Tanaka[Efficacy of anti-cytokines and anti-RANKL antibody for treatment of RA and osteoporosis].
000160 (2009) Kazuyoshi Saito ; Yoshiya Tanaka[New biologic and non biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis].
000300 (2011) Hisashi Yamanaka [Japon] ; Yoshiya Tanaka ; Eisuke Inoue ; Daisuke Hoshi ; Shigeki Momohara ; Kentaro Hanami ; Naoki Yunoue ; Kazuyoshi Saito ; Kouichi Amano ; Hideto Kameda ; Tsutomu TakeuchiEfficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study).
000353 (2011) Takao Koike [Japon] ; Masayoshi Harigai [Japon] ; Shigeko Inokuma [Japon] ; Naoki Ishiguro [Japon] ; Junnosuke Ryu [Japon] ; Tsutomu Takeuchi [Japon] ; Yoshiya Tanaka [Japon] ; Hisashi Yamanaka [Japon] ; Koichi Fujii [Japon] ; Takunari Yoshinaga [Japon] ; Bruce Freundlich [États-Unis] ; Michio Suzukawa [Japon]Safety and effectiveness responses to etanercept for rheumatoid arthritis in Japan: a sub-analysis of a post-marketing surveillance study focusing on the duration of rheumatoid arthritis
000372 (2011) Masaaki Hiura [Japon] ; Shintaro Abe ; Akinari Tabaru ; Shohei Shimajiri ; Kentaro Hanami ; Kazuyoshi Saito ; Yoshiya Tanaka ; Masaru HaradaCase of severe liver damage after the induction of tocilizumab therapy for rheumatoid vasculitis.
000415 (2011) Tsutomu Takeuchi [Japon] ; Yoshiya Tanaka ; Koichi Amano ; Daisuke Hoshi ; Masao Nawata ; Hayato Nagasawa ; Eri Sato ; Kazuyoshi Saito ; Yuko Kaneko ; Shunsuke Fukuyo ; Takahiko Kurasawa ; Kentaro Hanami ; Hideto Kameda ; Hisashi YamanakaClinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients--REACTION 52-week study.
000437 (2011) Takao Koike [Japon] ; Masayoshi Harigai ; Shigeko Inokuma ; Naoki Ishiguro ; Junnosuke Ryu ; Tsutomu Takeuchi ; Syuji Takei ; Yoshiya Tanaka ; Kyoko Ito ; Hisashi YamanakaPostmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients.
000577 (2012) Ryoko Sakai [Japon] ; Michi Tanaka ; Toshihiro Nanki ; Kaori Watanabe ; Hayato Yamazaki ; Ryuji Koike ; Hayato Nagasawa ; Koichi Amano ; Kazuyoshi Saito ; Yoshiya Tanaka ; Satoshi Ito ; Takayuki Sumida ; Atsushi Ihata ; Yoshiaki Ishigatsubo ; Tatsuya Atsumi ; Takao Koike ; Atsuo Nakajima ; Naoto Tamura ; Takao Fujii ; Hiroaki Dobashi ; Shigeto Tohma ; Takahiko Sugihara ; Yukitaka Ueki ; Akira Hashiramoto ; Atsushi Kawakami ; Noboru Hagino ; Nobuyuki Miyasaka ; Masayoshi HarigaiDrug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules.
000692 (2012) Josef S. Smolen [Autriche] ; Monika M. Schoels [Autriche] ; Norihiro Nishimoto [Japon] ; Ferdinand C. Breedveld [Pays-Bas] ; Gerd R. Burmester [Allemagne] ; Maxime Dougados [France] ; Paul Emery [Royaume-Uni] ; Gianfranco Ferraccioli [Italie] ; Cem Gabay [Suisse] ; Allan Gibofsky [États-Unis] ; Juan Jesus Gomez-Reino [Espagne] ; Graeme Jones [Australie] ; Tore K. Kvien [Norvège] ; Miho Murakami [Japon] ; Neil Betteridge [Royaume-Uni] ; Clifton O. Bingham [États-Unis] ; Vivian Bykerk [Suisse] ; Ernest H. Choy [Royaume-Uni] ; Bernard Combe [France] ; Maurizio Cutolo [Italie] ; Winfried Graninger [Autriche] ; Angel Lanas [Espagne] ; Emilio Martin-Mola [Espagne] ; Carlomaurizio Montecucco [Italie] ; Mikkel Ostergaard [Danemark] ; Karel Pavelka [République tchèque] ; Andrea Rubbert-Roth [Allemagne] ; Naveed Sattar [Royaume-Uni] ; Marieke Scholte-Voshaar [Suisse] ; Yoshiya Tanaka [Japon] ; Michael Trauner [Autriche] ; Gabriele Valentini [Italie] ; Kevin L. Winthrop [États-Unis] ; Maarten De Wit [Pays-Bas] ; Désirée Van Der Heijde [Pays-Bas]Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions
000938 (2014) Takao Koike [Japon] ; Masayoshi Harigai ; Shigeko Inokuma ; Naoki Ishiguro ; Junnosuke Ryu ; Tsutomu Takeuchi ; Syuji Takei ; Yoshiya Tanaka ; Yoko Sano ; Hitomi Yaguramaki ; Hisashi YamanakaEffectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan.
000949 (2014) Ippei Miyagawa [Japon] ; Shingo Nakayamada ; Kazuyoshi Saito ; Kentaro Hanami ; Masao Nawata ; Norifumi Sawamukai ; Kazuhisa Nakano ; Kunihiro Yamaoka ; Yoshiya TanakaStudy on the safety and efficacy of tocilizumab, an anti-IL-6 receptor antibody, in patients with rheumatoid arthritis complicated with AA amyloidosis.
000951 (2014) Yoshiya Tanaka [Japon] ; Tsutomu Takeuchi ; Koichi Amano ; Kazuyoshi Saito ; Kentaro Hanami ; Masao Nawata ; Shunsuke Fukuyo ; Hideto Kameda ; Yuko Kaneko ; Takahiko Kurasawa ; Hayato Nagasawa ; Daisuke Hoshi ; Eri Sato ; Hisashi YamanakaEffect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors.
000D74 (2015) Atsushi Ogata ; Koichi Amano ; Hiroaki Dobashi ; Masayuki Inoo ; Tomonori Ishii ; Tsuyoshi Kasama ; Shinichi Kawai ; Atsushi Kawakami ; Tatsuya Koike ; Hisaaki Miyahara ; Toshiaki Miyamoto ; Yasuhiko Munakata ; Akira Murasawa ; Norihiro Nishimoto ; Noriyoshi Ogawa ; Tomohiro Ojima ; Hajime Sano ; Kenrin Shi ; Eisuke Shono ; Eiichi Suematsu ; Hiroki Takahashi ; Yoshiya Tanaka ; Hiroshi Tsukamoto ; Akira NomuraLongterm Safety and Efficacy of Subcutaneous Tocilizumab Monotherapy: Results from the 2-year Open-label Extension of the MUSASHI Study.
000D92 (2015) Ryoko Sakai [Japon] ; Soo-Kyung Cho [Japon] ; Toshihiro Nanki [Japon] ; Kaori Watanabe [Japon] ; Hayato Yamazaki [Japon] ; Michi Tanaka [Japon] ; Ryuji Koike [Japon] ; Yoshiya Tanaka [Japon] ; Kazuyoshi Saito [Japon] ; Shintaro Hirata [Japon] ; Koichi Amano [Japon] ; Hayato Nagasawa [Japon] ; Takayuki Sumida [Japon] ; Taichi Hayashi [Japon] ; Takahiko Sugihara [Japon] ; Hiroaki Dobashi [Japon] ; Shinsuke Yasuda [Japon] ; Tetsuji Sawada [Japon] ; Kazuhiko Ezawa [Japon] ; Atsuhisa Ueda [Japon] ; Takao Fujii [Japon] ; Kiyoshi Migita [Japon] ; Nobuyuki Miyasaka [Japon] ; Masayoshi Harigai [Japon]Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry.
000E93 (2016) Satoshi Kubo [Japon] ; Shingo Nakayamada [Japon] ; Kazuhisa Nakano [Japon] ; Shintaro Hirata [Japon] ; Shunsuke Fukuyo [Japon] ; Ippei Miyagawa [Japon] ; Kentaro Hanami [Japon] ; Kazuyoshi Saito [Japon] ; Yoshiya Tanaka [Japon]Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching.
000F49 (2015) Shintaro Hirata [Japon] ; Anthony Marotta [Canada] ; Yuan Gui [Canada] ; Kentaro Hanami [Japon] ; Yoshiya Tanaka [Japon]Serum 14-3-3η level is associated with severity and clinical outcomes of rheumatoid arthritis, and its pretreatment level is predictive of DAS28 remission with tocilizumab.
001031 (2016) Yuko Kaneko [Japon] ; Tatsuya Atsumi [Japon] ; Yoshiya Tanaka [Japon] ; Masayuki Inoo [Japon] ; Hitomi Kobayashi-Haraoka [Japon] ; Koichi Amano [Japon] ; Masayuki Miyata [Japon] ; Yohko Murakawa [Japon] ; Hidekata Yasuoka [Japon] ; Shintaro Hirata [Japon] ; Hayato Nagasawa [Japon] ; Eiichi Tanaka [Japon] ; Nobuyuki Miyasaka [Japon] ; Hisashi Yamanaka [Japon] ; Kazuhiko Yamamoto [Japon] ; Tsutomu Takeuchi [Japon]Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study).
001257 (2017) Naoki Ishiguro [Japon] ; Tatsuya Atsumi [Japon] ; Masayoshi Harigai [Japon] ; Tsuneyo Mimori [Japon] ; Norihiro Nishimoto [Japon] ; Takayuki Sumida [Japon] ; Tsutomu Takeuchi [Japon] ; Yoshiya Tanaka [Japon] ; Ayako Nakasone [Japon] ; Nobuhiro Takagi ; Hisashi Yamanaka [Japon]Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naive patients with rheumatoid arthritis: The FIRST Bio study.
001470 (2017) Stanley B. Cohen [États-Unis] ; Yoshiya Tanaka [Japon] ; Xavier Mariette [France] ; Jeffrey R. Curtis [États-Unis] ; Eun Bong Lee [Corée du Sud] ; Peter Nash [Australie] ; Kevin L. Winthrop [États-Unis] ; Christina Charles-Schoeman [États-Unis] ; Krishan Thirunavukkarasu [Australie] ; Ryan Demasi [États-Unis] ; Jamie Geier [États-Unis] ; Kenneth Kwok [États-Unis] ; Lisy Wang [États-Unis] ; Richard Riese [États-Unis] ; Jürgen Wollenhaupt [Allemagne]Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials
001538 (2018) Shingo Nakayamada [Japon] ; Satoshi Kubo [Japon] ; Maiko Yoshikawa [Japon] ; Yusuke Miyazaki [Japon] ; Naoki Yunoue [Japon] ; Shigeru Iwata [Japon] ; Ippei Miyagawa [Japon] ; Shintaro Hirata [Japon] ; Kazuhisa Nakano [Japon] ; Kazuyoshi Saito [Japon] ; Yoshiya Tanaka [Japon]Differential effects of biological DMARDs on peripheral immune cell phenotypes in patients with rheumatoid arthritis.
001622 (2018) Atsushi Ogata [Japon] ; Yoshiya Tanaka [Japon] ; Tomonori Ishii [Japon] ; Motohide Kaneko [Japon] ; Hiroko Miwa [Japon] ; Shino Ohsawa [Japon]A randomized, double-blind, parallel-group, phase III study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: Results of the 12-week double-blind period.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Ncbi/Checkpoint
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/Author.i -k "Yoshiya Tanaka" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/Author.i  \
                -Sk "Yoshiya Tanaka" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Ncbi
   |étape=   Checkpoint
   |type=    indexItem
   |index=    Author.i
   |clé=    Yoshiya Tanaka
}}

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021